BridgeBio reported data showing its oral FGFR3 inhibitor infigratinib matched the height outcomes achieved by Voxzogo (vosoritide) in achondroplasia patients, while offering an oral dosing option. The company is preparing regulatory submissions based on the readouts. FGFR3 is the validated biological target in achondroplasia, and an effective oral alternative could shift prescribing patterns and payer negotiations in the rare‑disease market. BridgeBio’s data positions infigratinib as a potential competitor to the injected standard of care and underscores a broader industry focus on converting parenteral biologic benefits into oral small‑molecule formats.